Drug shortages
Supply-availability records maintained by the FDA Drug Shortages program. A record tracks whether a specific presentation is available, limited, or unavailable, and the reason the manufacturer gave. Shortages are common and often resolve; always confirm current supply with a dispensing pharmacy.
1,601 records · 1,153 current · source: FDA Drug Shortages
| Status | Availability | Generic name | Presentation | Company | Updated |
|---|---|---|---|---|---|
| Current | Available | Clonazepam Tablet | Clonazepam, Tablet, 2 mg (NDC 59651-724-05) | Aurobindo Pharma USA | June 2, 2026 |
| Current | Unavailable | Quinapril/Hydrochlorothiazide Tablet | Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 12.5 mg; 20 mg (NDC 65862-162-90) | Aurobindo Pharma USA | June 2, 2026 |
| Current | Unavailable | Quinapril/Hydrochlorothiazide Tablet | Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 25 mg; 20 mg (NDC 65862-163-90) | Aurobindo Pharma USA | June 2, 2026 |
| Current | Available | Clonazepam Tablet | Clonazepam, Tablet, 2 mg (NDC 59651-724-01) | Aurobindo Pharma USA | June 2, 2026 |
| Current | Unavailable | Quinapril/Hydrochlorothiazide Tablet | Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 12.5 mg; 10 mg (NDC 65862-161-90) | Aurobindo Pharma USA | June 2, 2026 |
| Current | Available | Clonazepam Tablet | Clonazepam, Tablet, .5 mg (NDC 59651-722-99) | Aurobindo Pharma USA | June 2, 2026 |
| Current | Unavailable | Quinapril Hydrochloride Tablet | Quinapril Hydrochloride, Tablet, 5 mg (NDC 65862-617-90) | Aurobindo Pharma USA | June 2, 2026 |
| Current | Available | Clonazepam Tablet | Clonazepam, Tablet, .5 mg (NDC 59651-722-01) | Aurobindo Pharma USA | June 2, 2026 |
| Current | Available | Clonazepam Tablet | Clonazepam, Tablet, 1 mg (NDC 59651-723-01) | Aurobindo Pharma USA | June 2, 2026 |
| Current | Unavailable | Quinapril Hydrochloride Tablet | Quinapril Hydrochloride, Tablet, 10 mg (NDC 65862-618-90) | Aurobindo Pharma USA | June 2, 2026 |
| Current | Unavailable | Quinapril Hydrochloride Tablet | Quinapril Hydrochloride, Tablet, 10 mg (NDC 65862-618-90) | Aurobindo Pharma USA | June 2, 2026 |
| Current | Available | Clonazepam Tablet | Clonazepam, Tablet, 1 mg (NDC 59651-723-99) | Aurobindo Pharma USA | June 2, 2026 |
| Current | Unavailable | Quinapril Hydrochloride Tablet | Quinapril Hydrochloride, Tablet, 40 mg (NDC 65862-620-90) | Aurobindo Pharma USA | June 2, 2026 |
| Current | Available | Clonazepam Tablet | Clonazepam, Tablet, .5 mg (NDC 72888-152-30) | Rubicon Research Private Limited | June 1, 2026 |
| To Be Discontinued | Clindamycin Phosphate Injection | Cleocin Phosphate, Injection, 600 mg/4 mL (150 mg/mL); 4 mL Vial NovaPlus (NDC… | Pfizer Inc. | June 1, 2026 | |
| To Be Discontinued | Clindamycin Phosphate Injection | Cleocin Phosphate, Injection, 900 mg/6 mL (150 mg/mL); 6 mL Vial (NDC 0009-0902-18) | Pfizer Inc. | June 1, 2026 | |
| Current | Available | Clonazepam Tablet | Clonazepam, Tablet, .5 mg (NDC 72888-152-01) | Rubicon Research Private Limited | June 1, 2026 |
| Current | Available | Clonazepam Tablet | Clonazepam, Tablet, 2 mg (NDC 72888-154-01) | Rubicon Research Private Limited | June 1, 2026 |
| Current | Available | Clonazepam Tablet | Clonazepam, Tablet, 2 mg (NDC 72888-154-05) | Rubicon Research Private Limited | June 1, 2026 |
| Current | Available | Clonazepam Tablet | Clonazepam, Tablet, 1 mg (NDC 72888-153-30) | Rubicon Research Private Limited | June 1, 2026 |
| Current | Available | Clonazepam Tablet | Clonazepam, Tablet, 1 mg (NDC 72888-153-05) | Rubicon Research Private Limited | June 1, 2026 |
| Current | Available | Clonazepam Tablet | Clonazepam, Tablet, .5 mg (NDC 72888-152-00) | Rubicon Research Private Limited | June 1, 2026 |
| To Be Discontinued | Carboplatin Injection | Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-1) | Teyro Labs | June 1, 2026 | |
| To Be Discontinued | Clindamycin Phosphate Injection | Cleocin Phosphate, Injection, 600 mg/4 mL (150 mg/mL); 4 mL Vial (NDC 0009-0775-26) | Pfizer Inc. | June 1, 2026 | |
| Current | Available | Clonazepam Tablet | Clonazepam, Tablet, 2 mg (NDC 72888-154-30) | Rubicon Research Private Limited | June 1, 2026 |
| To Be Discontinued | Clindamycin Phosphate Injection | Cleocin Phosphate, Injection, 300 mg/2 mL (150 mg/mL); 2 mL Vial (NDC 0009-0870-26) | Pfizer Inc. | June 1, 2026 | |
| To Be Discontinued | Clindamycin Phosphate Injection | Cleocin Phosphate, Injection, 900 mg/6 mL (150 mg/mL); 6 mL Vial NovaPlus (NDC… | Pfizer Inc. | June 1, 2026 | |
| To Be Discontinued | Carboplatin Injection | Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-7) | Teyro Labs | June 1, 2026 | |
| Current | Available | Clonazepam Tablet | Clonazepam, Tablet, 1 mg (NDC 72888-153-00) | Rubicon Research Private Limited | June 1, 2026 |
| Current | Unavailable | Bacitracin Ophthalmic Ointment | Bacitracin, Ophthalmic Ointment, 3.5 g (NDC 0574-4022-35) | Padagis US LLC | June 1, 2026 |
| Current | Available | Clonazepam Tablet | Clonazepam, Tablet, .5 mg (NDC 72888-152-05) | Rubicon Research Private Limited | June 1, 2026 |
| Current | Available | Clonazepam Tablet | Clonazepam, Tablet, 1 mg (NDC 72888-153-01) | Rubicon Research Private Limited | June 1, 2026 |
| To Be Discontinued | Clindamycin Phosphate Injection | Cleocin Phosphate, Injection, 300 mg/2 mL (150 mg/mL); 2 mL Vial NovaPlus (NDC… | Pfizer Inc. | June 1, 2026 | |
| To Be Discontinued | Carboplatin Injection | Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-6) | Teyro Labs | June 1, 2026 | |
| To Be Discontinued | Carboplatin Injection | Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-3) | Teyro Labs | June 1, 2026 | |
| To Be Discontinued | Dehydrated Alcohol Injection, Solution | Dehydrated Alcohol, Injection, Solution, 1 mL/1 mL (10 pack) (NDC 16729-710-45) | Accord Healthcare Inc. | May 27, 2026 | |
| To Be Discontinued | Alteplase Injection | Activase, Injection, 1 KIT in 1 CARTON (50242-085-27) * 100 mL in 1 VIAL, SINGLE-USE *… | Genentech, Inc | May 21, 2026 | |
| To Be Discontinued | Iron Sucrose Injection | Iron Sucrose, Injection, 50 mg/2.5 mL (NDC 67457-957-99) | Mylan Institutional, a Viatris Company | May 21, 2026 | |
| To Be Discontinued | Gadoterate Meglumine Injection | Gadoterate Meglumine, Injection, 376.9 mg/1 mL (NDC 65219-080-05) | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | May 21, 2026 | |
| To Be Discontinued | Gadoterate Meglumine Injection | Gadoterate Meglumine, Injection, 376.9 mg/1 mL (NDC 65219-084-15) | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | May 21, 2026 | |
| To Be Discontinued | Gadoterate Meglumine Injection | Gadoterate Meglumine, Injection, 376.9 mg/1 mL (NDC 65219-086-20) | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | May 21, 2026 | |
| To Be Discontinued | Gadoterate Meglumine Injection | Gadoterate Meglumine, Injection, 376.9 mg/1 mL (NDC 65219-082-10) | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | May 21, 2026 | |
| To Be Discontinued | Activated Charcoal Oral Suspension | Actidose Aqua, Oral Suspension, 208 mg/1 mL (NDC 0574-0521-76) | Padagis US LLC | May 15, 2026 | |
| Current | Available | Ketorolac Tromethamine Injection | Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 62332-599-25) | Alembic Pharmaceuticals | May 15, 2026 |
| To Be Discontinued | Activated Charcoal Oral Suspension | Actidose Aqua, Oral Suspension, 208 mg/1 mL (NDC 0574-0521-74) | Padagis US LLC | May 15, 2026 | |
| To Be Discontinued | Activated Charcoal Oral Suspension | Actidose Aqua, Oral Suspension, 208 mg/1 mL (NDC 0574-0521-25) | Padagis US LLC | May 15, 2026 | |
| Current | Unavailable | Lidocaine Hydrochloride Injection | Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 65282-1605-1) | Spectra Medical Devices, LLC | May 15, 2026 |
| Current | Available | Ketorolac Tromethamine Injection | Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 62332-600-25) | Alembic Pharmaceuticals | May 15, 2026 |
| Current | Available | Ketorolac Tromethamine Injection | Ketorolac Tromethamine, Injection, 60 mg/2 mL (NDC 62332-601-25) | Alembic Pharmaceuticals | May 15, 2026 |
| To Be Discontinued | Activated Charcoal Oral Suspension | Actidose, Oral Suspension, 208 mg/1 mL (NDC 0574-0520-74) | Padagis US LLC | May 15, 2026 | |
| To Be Discontinued | Activated Charcoal Oral Suspension | Actidose, Oral Suspension, 208 mg/1 mL (NDC 0574-0520-76) | Padagis US LLC | May 15, 2026 | |
| To Be Discontinued | Liraglutide Injection | Liraglutide, Injection, 6 mg/1 mL (NDC 0480-7250-46) | Teva Pharmaceuticals USA, Inc. | May 14, 2026 | |
| Current | Limited Availability | Lisdexamfetamine Dimesylate Capsule | Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0054-0660-25) | Hikma Pharmaceuticals USA, Inc. | May 12, 2026 |
| To Be Discontinued | Sulconazole Nitrate Solution | Exelderm, Solution, 1.0% 5 mL (NDC 69489-721-05) | Journey Medical Corporation | May 8, 2026 | |
| To Be Discontinued | Sulconazole Nitrate Solution | Sulconazole Nitrate, Solution, 30 mL (NDC 72143-321-30) | Journey Medical Corporation | May 8, 2026 | |
| To Be Discontinued | Sulconazole Nitrate Solution | Exelderm, Solution, 1.0% 30 mL (NDC 69489-721-30) | Journey Medical Corporation | May 8, 2026 | |
| To Be Discontinued | Icatibant Acetate Injection | Icatibant Acetate, Injection, 10 mg/1 mL (NDC 63323-574-93) | Fresenius Kabi USA, LLC | May 7, 2026 | |
| To Be Discontinued | Icatibant Acetate Injection | Icatibant Acetate, Injection, 10 mg/1 mL (NDC 63323-574-86) | Fresenius Kabi USA, LLC | May 7, 2026 | |
| To Be Discontinued | Cisatracurium Besylate Injection | Cisatracurium Besylate, Injection, 20 mg/10 mL (2 mg/mL) Multidose Vial (NDC 0409-1208-01) | Hospira, Inc., a Pfizer Company | May 6, 2026 | |
| To Be Discontinued | Cisatracurium Besylate Injection | Cisatracurium Besylate, Injection, 200 mg/20ml (10 mg/mL) Single Dose Vial (NDC… | Hospira, Inc., a Pfizer Company | May 6, 2026 | |
| Current | Limited Availability | Bupivacaine Hydrochloride Injection | Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-722-32) | Kindos Pharmaceuticals Co. Ltd. | May 5, 2026 |
| Current | Limited Availability | Bupivacaine Hydrochloride Injection | Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-723-52) | Kindos Pharmaceuticals Co. Ltd. | May 5, 2026 |
| Current | Limited Availability | Bupivacaine Hydrochloride Injection | Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-726-52) | Kindos Pharmaceuticals Co. Ltd. | May 5, 2026 |
| Current | Limited Availability | Bupivacaine Hydrochloride Injection | Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-725-32) | Kindos Pharmaceuticals Co. Ltd. | May 5, 2026 |
| To Be Discontinued | Bupivacaine Hydrochloride Injection | Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-726-52) | Kindos Pharmaceuticals Co. Ltd. | May 5, 2026 | |
| To Be Discontinued | Bupivacaine Hydrochloride Injection | Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-722-32) | Kindos Pharmaceuticals Co. Ltd. | May 5, 2026 | |
| To Be Discontinued | Bupivacaine Hydrochloride Injection | Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-723-52) | Kindos Pharmaceuticals Co. Ltd. | May 5, 2026 | |
| Current | Limited Availability | Bupivacaine Hydrochloride Injection | Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 71288-728-32) | Kindos Pharmaceuticals Co. Ltd. | May 5, 2026 |
| To Be Discontinued | Bupivacaine Hydrochloride Injection | Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-725-32) | Kindos Pharmaceuticals Co. Ltd. | May 5, 2026 | |
| To Be Discontinued | Bupivacaine Hydrochloride Injection | Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 71288-728-32) | Kindos Pharmaceuticals Co. Ltd. | May 5, 2026 | |
| Current | Unavailable | Desmopressin Acetate Spray | Ddavp, Spray, .1 ug/1 mL (NDC 55566-2500-0) | Ferring | May 1, 2026 |
| Current | Unavailable | Desmopressin Acetate Spray | Desmopressin Acetate, Spray, 10 ug/.1 mL (NDC 69918-501-05) | Ferring | May 1, 2026 |
| Current | Unavailable | Desmopressin Acetate Spray | Stimate, Spray, 1.5 mg/1 mL (NDC 0053-6871-00) | Ferring | May 1, 2026 |
| To Be Discontinued | Lamotrigine Tablet, Extended Release | Lamotrigine, Tablet, Extended Release, 100 mg (NDC 49884-563-11) | Par Health, Inc. | April 29, 2026 | |
| To Be Discontinued | Lamotrigine Tablet, Extended Release | Lamotrigine, Tablet, Extended Release, 250 mg (NDC 49884-604-11) | Par Health, Inc. | April 29, 2026 | |
| To Be Discontinued | Lamotrigine Tablet, Extended Release | Lamotrigine, Tablet, Extended Release, 25 mg (NDC 49884-561-11) | Par Health, Inc. | April 29, 2026 | |
| To Be Discontinued | Lamotrigine Tablet, Extended Release | Lamotrigine, Tablet, Extended Release, 300 mg (NDC 49884-605-11) | Par Health, Inc. | April 29, 2026 | |
| To Be Discontinued | Lamotrigine Tablet, Extended Release | Lamotrigine, Tablet, Extended Release, 50 mg (NDC 49884-562-11) | Par Health, Inc. | April 29, 2026 | |
| To Be Discontinued | Lamotrigine Tablet, Extended Release | Lamotrigine, Tablet, Extended Release, 200 mg (NDC 49884-564-11) | Par Health, Inc. | April 29, 2026 | |
| To Be Discontinued | Furosemide Injection | Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-10) | Gland Pharma Limited | April 28, 2026 | |
| To Be Discontinued | Furosemide Injection | Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-02) | Gland Pharma Limited | April 28, 2026 | |
| To Be Discontinued | Etravirine Tablet | Etravirine, Tablet, 100 mg (NDC 10147-0570-1) | Janssen Research and Development | April 28, 2026 | |
| To Be Discontinued | Furosemide Injection | Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-04) | Gland Pharma Limited | April 28, 2026 | |
| To Be Discontinued | Etravirine Tablet | Intelence, Tablet, 100 mg (NDC 59676-570-01) | Janssen Research and Development | April 28, 2026 | |
| To Be Discontinued | Crinecerfont Capsule | Crenessity, Capsule, 25 mg (NDC 70370-5025-1) | Neurocrine Biosciences, Inc. | April 28, 2026 | |
| To Be Discontinued | Palbociclib Capsule | Ibrance, Capsule, 100 mg (NDC 0069-0188-21) | Pfizer Inc. | April 22, 2026 | |
| To Be Discontinued | Palbociclib Capsule | Ibrance, Capsule, 75 mg (NDC 0069-0187-21) | Pfizer Inc. | April 22, 2026 | |
| To Be Discontinued | Dexmedetomidine Hydrochloride Injection | Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 16729-239-93) | Accord Healthcare Inc. | April 21, 2026 | |
| To Be Discontinued | Rifampin Injection | Rifadin, Injection, 600 mg/10 mL (NDC 0068-0597-01) | Sanofi-Aventis U.S. LLC | April 20, 2026 | |
| To Be Discontinued | Ketorolac Tromethamine Tablet | Ketorolac Tromethamine, Tablet, 10 mg (NDC 0378-1134-01) | Mylan Pharmaceuticals Inc., a Viatris Company | April 20, 2026 | |
| To Be Discontinued | Tiagabine Hydrochloride Tablet | Tiagabine Hydrochloride, Tablet, 4mg 30 count (NDC 0093-5031-56) | Teva Pharmaceuticals USA, Inc. | April 15, 2026 | |
| To Be Discontinued | Tiagabine Hydrochloride Tablet | Tiagabine Hydrochloride, Tablet, 16mg 30 count (NDC 0093-8076-56) | Teva Pharmaceuticals USA, Inc. | April 15, 2026 | |
| To Be Discontinued | Tiagabine Hydrochloride Tablet | Tiagabine Hydrochloride, Tablet, 12mg 30 count (NDC 0093-8072-56) | Teva Pharmaceuticals USA, Inc. | April 15, 2026 | |
| To Be Discontinued | Tiagabine Hydrochloride Tablet | Tiagabine Hydrochloride, Tablet, 2mg 30 count (NDC 0093-5030-56) | Teva Pharmaceuticals USA, Inc. | April 15, 2026 | |
| To Be Discontinued | Nitroglycerin Ointment | Rectiv, Ointment, 0.4% (NDC 58914-301-80) | AbbVie Inc. | April 14, 2026 | |
| To Be Discontinued | Nitrofurantoin Oral Suspension | Nitrofurantoin, Oral Suspension, 25 mg/5 mL (NDC 69238-2512-9) | Amneal Pharmaceuticals | April 10, 2026 | |
| To Be Discontinued | Azithromycin Tablet | Zithromax, Tablet, 500 mg (NDC 0069-3070-30) | Pfizer Inc. | April 9, 2026 | |
| To Be Discontinued | Azithromycin Tablet | Zithromax, Tablet, 250 mg (NDC 0069-4061-01) | Pfizer Inc. | April 9, 2026 | |
| To Be Discontinued | Aprepitant Oral Powder for Suspension | Emend, Oral Powder for Suspension, 125 mg (NDC 0006-3066-03) | Merck Sharp & Dohme LLC | April 8, 2026 | |
| To Be Discontinued | Fosaprepitant Dimeglumine Injection | Fosaprepitant Dimeglumine, Injection, 150 mg/5 mL (NDC 63323-972-10) | Fresenius Kabi USA, LLC | April 8, 2026 | |
| To Be Discontinued | Idelalisib Tablet | Zydelig, Tablet, 150 mg (NDC 61958-1702-1) | Gilead Sciences, Inc. | April 7, 2026 | |
| To Be Discontinued | Idelalisib Tablet | Zydelig, Tablet, 100 mg (NDC 61958-1701-1) | Gilead Sciences, Inc. | April 7, 2026 | |
| To Be Discontinued | Ursodiol Capsule | Ursodiol, Capsule, 300 mg (NDC 64380-844-06) | Strides Pharma Inc. | April 6, 2026 | |
| To Be Discontinued | Icosapent Ethyl Capsule | Icosapent Ethyl, Capsule, 1 g (NDC 60429-005-12) | Apotex Corp. | April 1, 2026 | |
| To Be Discontinued | Icosapent Ethyl Capsule | Icosapent Ethyl, Capsule, 1 g (NDC 61474-9711-1) | Apotex Corp. | April 1, 2026 | |
| To Be Discontinued | Dapsone Gel | Dapsone, Gel, 7.5% (NDC 69238-1627-6) | Amneal Pharmaceuticals | March 27, 2026 | |
| To Be Discontinued | Progesterone Vaginal Gel | Crinone, Vaginal Gel, 4% (NDC 0023-6150-04) | AbbVie Inc. | March 27, 2026 | |
| To Be Discontinued | Tazemetostat Hydrobromide Tablet | Tazverik, Tablet, 200 mg (NDC 72607-100-00) | Epizyme, Inc. (An Ipsen Company) | March 27, 2026 | |
| To Be Discontinued | Clindamycin Palmitate Hydrochloride Injection | Clindamycin Palmitate Hydrochloride, Injection, 75 mg/5 mL (NDC 53746-468-19) | Amneal Pharmaceuticals | March 26, 2026 | |
| To Be Discontinued | Lincomycin Hydrochloride Injection | Lincomycin Hydrochloride, Injection, 600 mg/2 mL vial x 10 count (NDC 39822-0350-2) | XGen Pharmaceuticals DJB, Inc. | March 26, 2026 | |
| To Be Discontinued | Lincomycin Hydrochloride Injection | Lincomycin Hydrochloride, Injection, 3 grams/10 mL vial x 10 count (NDC 39822-0355-6) | XGen Pharmaceuticals DJB, Inc. | March 26, 2026 | |
| To Be Discontinued | Nebivolol Hydrochloride Tablet | Nebivolol Hydrochloride, Tablet, 2.5 mg (NDC 13668-353-05) | Torrent Pharmaceuticals Limited | March 25, 2026 | |
| To Be Discontinued | Nebivolol Hydrochloride Tablet | Nebivolol Hydrochloride, Tablet, 10 mg (NDC 13668-355-05) | Torrent Pharmaceuticals Limited | March 25, 2026 | |
| To Be Discontinued | Nebivolol Hydrochloride Tablet | Nebivolol Hydrochloride, Tablet, 5 mg (NDC 13668-354-01) | Torrent Pharmaceuticals Limited | March 25, 2026 | |
| To Be Discontinued | Nebivolol Hydrochloride Tablet | Nebivolol Hydrochloride, Tablet, 10 mg (NDC 13668-355-30) | Torrent Pharmaceuticals Limited | March 25, 2026 | |
| To Be Discontinued | Nebivolol Hydrochloride Tablet | Nebivolol Hydrochloride, Tablet, 5 mg (NDC 13668-354-05) | Torrent Pharmaceuticals Limited | March 25, 2026 | |
| To Be Discontinued | Nebivolol Hydrochloride Tablet | Nebivolol Hydrochloride, Tablet, 20 mg (NDC 13668-356-30) | Torrent Pharmaceuticals Limited | March 25, 2026 | |
| To Be Discontinued | Nebivolol Hydrochloride Tablet | Nebivolol Hydrochloride, Tablet, 5 mg (NDC 13668-354-90) | Torrent Pharmaceuticals Limited | March 25, 2026 | |
| To Be Discontinued | Nebivolol Hydrochloride Tablet | Nebivolol Hydrochloride, Tablet, 2.5 mg (NDC 13668-353-90) | Torrent Pharmaceuticals Limited | March 25, 2026 | |
| To Be Discontinued | Nebivolol Hydrochloride Tablet | Nebivolol Hydrochloride, Tablet, 10 mg (NDC 13668-355-01) | Torrent Pharmaceuticals Limited | March 25, 2026 | |
| To Be Discontinued | Nebivolol Hydrochloride Tablet | Nebivolol Hydrochloride, Tablet, 20 mg (NDC 13668-356-01) | Torrent Pharmaceuticals Limited | March 25, 2026 | |
| To Be Discontinued | Nebivolol Hydrochloride Tablet | Nebivolol Hydrochloride, Tablet, 20 mg (NDC 13668-356-05) | Torrent Pharmaceuticals Limited | March 25, 2026 | |
| To Be Discontinued | Nebivolol Hydrochloride Tablet | Nebivolol Hydrochloride, Tablet, 10 mg (NDC 13668-355-90) | Torrent Pharmaceuticals Limited | March 25, 2026 | |
| To Be Discontinued | Nebivolol Hydrochloride Tablet | Nebivolol Hydrochloride, Tablet, 20 mg (NDC 13668-356-90) | Torrent Pharmaceuticals Limited | March 25, 2026 | |
| To Be Discontinued | Nebivolol Hydrochloride Tablet | Nebivolol Hydrochloride, Tablet, 2.5 mg (NDC 13668-353-01) | Torrent Pharmaceuticals Limited | March 25, 2026 | |
| To Be Discontinued | Nebivolol Hydrochloride Tablet | Nebivolol Hydrochloride, Tablet, 2.5 mg (NDC 13668-353-30) | Torrent Pharmaceuticals Limited | March 25, 2026 | |
| To Be Discontinued | Nebivolol Hydrochloride Tablet | Nebivolol Hydrochloride, Tablet, 5 mg (NDC 13668-354-30) | Torrent Pharmaceuticals Limited | March 25, 2026 | |
| To Be Discontinued | Pilocarpine Hydrochloride Ophthalmic Solution | Vuity, Ophthalmic Solution, 12.5 mg/1 mL (NDC 0074-7098-05) | AbbVie Inc. | March 24, 2026 | |
| To Be Discontinued | Pilocarpine Hydrochloride Ophthalmic Solution | Vuity, Ophthalmic Solution, 12.5 mg/1 mL (NDC 0074-7098-03) | AbbVie Inc. | March 24, 2026 | |
| To Be Discontinued | Pilocarpine Hydrochloride Ophthalmic Solution | Vuity, Ophthalmic Solution, 12.5 mg/1 mL (NDC 0074-7098-06) | AbbVie Inc. | March 24, 2026 | |
| To Be Discontinued | Ivabradine Solution | Corlanor, Solution, 5 mg/5 mL (NDC 55513-813-28) | Amgen Inc. | March 24, 2026 | |
| To Be Discontinued | Ivabradine Hydrochloride Tablet | Corlanor, Tablet, eq. 5 mg base (NDC 55513-800-60) | Amgen Inc. | March 24, 2026 | |
| To Be Discontinued | Pilocarpine Hydrochloride Ophthalmic Solution | Vuity, Ophthalmic Solution, 12.5 mg/1 mL (NDC 0074-7098-01) | AbbVie Inc. | March 24, 2026 | |
| To Be Discontinued | Ivabradine Hydrochloride Tablet | Corlanor, Tablet, eq. 7.5 mg base (NDC 55513-810-60) | Amgen Inc. | March 24, 2026 | |
| To Be Discontinued | Pilocarpine Hydrochloride Ophthalmic Solution | Vuity, Ophthalmic Solution, 12.5 mg/1 mL (NDC 0074-7098-04) | AbbVie Inc. | March 24, 2026 | |
| To Be Discontinued | Pentamidine Isethionate Injection | Pentamidine Isethionate, Injection, 300 mg/3 mL (NDC 39822-3050-2) | XGen Pharmaceuticals DJB, Inc. | March 23, 2026 | |
| To Be Discontinued | Ramelteon Tablet | Rozerem, Tablet, 8 mg (NDC 64764-805-30) | Takeda Pharmaceuticals USA Inc. | March 19, 2026 | |
| To Be Discontinued | Ramelteon Tablet | Rozerem, Tablet, 8 mg (NDC 64764-805-10) | Takeda Pharmaceuticals USA Inc. | March 19, 2026 | |
| To Be Discontinued | Plerixafor Injection | Plerixafor, Injection, 24 mg per 1.2 mL (20 mg per mL) (NDC 65219-284-12) | Fresenius Kabi USA, LLC | March 13, 2026 | |
| To Be Discontinued | Peritoneal Dialysis Solution | DELFLEX® w/Dextrose, Solution, 4.25% Low Mg/Low Ca 2.5L/3L, 5/cs (NDC 46163-212-94) | Fresenius Medical Care North America | March 10, 2026 | |
| To Be Discontinued | Peritoneal Dialysis Solution | DELFLEX® w/Dextrose, Solution, 4.25% Low Mg/Low Ca 2L, 5/cs (NDC 46163-212-92) | Fresenius Medical Care North America | March 10, 2026 | |
| To Be Discontinued | Peritoneal Dialysis Solution | DELFLEX® w/Dextrose, Solution, 2.5% Low Mg/Low Ca 2.5L/3L, 5/cs (NDC 49230-209-94) | Fresenius Medical Care North America | March 10, 2026 | |
| To Be Discontinued | Peritoneal Dialysis Solution | DELFLEX® w/Dextrose, Solution, 1.5% Low Mg/Low Ca 2L, 5/cs (NDC 46163-206-92) | Fresenius Medical Care North America | March 10, 2026 | |
| To Be Discontinued | Peritoneal Dialysis Solution | DELFLEX® w/Dextrose, Solution, 2.5% Low Mg/Low Ca 2L, 5/cs (NDC 49230-209-92) | Fresenius Medical Care North America | March 10, 2026 | |
| To Be Discontinued | Peritoneal Dialysis Solution | DELFLEX® w/Dextrose, Solution, 1.5% Low Mg/Low Ca 2.5L/3L, 5/cs (NDC 49230-206-94) | Fresenius Medical Care North America | March 10, 2026 | |
| To Be Discontinued | Everolimus Tablet | Everolimus, Tablet, 10 mg (NDC 0093-7769-24) | Teva Pharmaceuticals USA, Inc. | March 2, 2026 | |
| To Be Discontinued | Everolimus Tablet | Everolimus, Tablet, 5 mg (NDC 0093-7767-24) | Teva Pharmaceuticals USA, Inc. | March 2, 2026 | |
| To Be Discontinued | Everolimus Tablet | Everolimus, Tablet, 2.5 mg (NDC 0093-7766-24) | Teva Pharmaceuticals USA, Inc. | March 2, 2026 | |
| To Be Discontinued | Everolimus Tablet | Everolimus, Tablet, 7.5 mg (NDC 0093-7768-24) | Teva Pharmaceuticals USA, Inc. | March 2, 2026 | |
| To Be Discontinued | Itraconazole Capsule | Sporanox, Capsule, 100 mg (NDC 50458-290-01) | Janssen Pharmaceuticals | February 27, 2026 | |
| To Be Discontinued | Clindamycin Palmitate Hydrochloride Injection | Clindamycin Palmitate Hydrochloride, Injection, 75 mg/5 mL (NDC 53746-468-19) | Amneal Pharmaceuticals | February 27, 2026 | |
| To Be Discontinued | Itraconazole Capsule | Sporanox, Capsule, 100 mg (NDC 10147-1700-3) | Janssen Pharmaceuticals | February 27, 2026 | |
| To Be Discontinued | Itraconazole Capsule | Sporanox, Capsule, 100 mg (NDC 50458-290-04) | Janssen Pharmaceuticals | February 27, 2026 | |
| To Be Discontinued | Lincomycin Hydrochloride Injection | Lincocin, Injection, 2 mL multiple dose vial (NDC 0009-0104-04) | Pfizer Inc. | February 25, 2026 | |
| To Be Discontinued | Clindamycin Hydrochloride Capsule | Cleocin Hydrochloride, Capsule, 300 mg (NDC 0009-0395-14) | Pfizer Inc. | February 25, 2026 | |
| To Be Discontinued | Oxaliplatin Injection | Oxaliplatin, Injection, 5 mg/mL (NDC 63323-750-10) | Fresenius Kabi USA, LLC | February 25, 2026 | |
| To Be Discontinued | Oxaliplatin Injection | Oxaliplatin, Injection, 5 mg/mL (NDC 63323-750-20) | Fresenius Kabi USA, LLC | February 25, 2026 | |
| To Be Discontinued | Clindamycin Hydrochloride Capsule | Cleocin Hydrochloride, Capsule, 150 mg (NDC 0009-0225-02) | Pfizer Inc. | February 25, 2026 | |
| To Be Discontinued | Clindamycin Hydrochloride Capsule | Cleocin Hydrochloride, Capsule, 75 mg (NDC 0009-0331-02) | Pfizer Inc. | February 25, 2026 | |
| To Be Discontinued | Arsenic Trioxide Injection | Arsenic Trioxide, Injection, 1 mg/1 mL (NDC 50742-438-10) | Ingenus Pharmaceuticals LLC | February 24, 2026 | |
| To Be Discontinued | Frovatriptan Succinate Tablet | Frova, Tablet, 2.5 mg (NDC 63481-025-09) | Endo Pharmaceuticals, Inc. | February 24, 2026 | |
| To Be Discontinued | Irinotecan Hydrochloride Injection | Irinotecan Hydrochloride, Injection, 40 mg/2 mL (NDC 50742-401-02) | Ingenus Pharmaceuticals LLC | February 24, 2026 | |
| To Be Discontinued | Irinotecan Hydrochloride Injection | Irinotecan Hydrochloride, Injection, 100 mg/5 mL (NDC 50742-402-05) | Ingenus Pharmaceuticals LLC | February 24, 2026 | |
| To Be Discontinued | Decitabine Injection | Decitabine, Injection, 50 mg (NDC 68001-573-41) | Ingenus Pharmaceuticals LLC | February 20, 2026 | |
| To Be Discontinued | Docetaxel Injection | Docetaxel, Injection, 10 mg/1 mL (NDC 50742-431-08) | Ingenus Pharmaceuticals LLC | February 20, 2026 | |
| To Be Discontinued | Carboplatin Injection | Carboplatin, Injection, 450 mg/45 mL (NDC 50742-447-45) | Ingenus Pharmaceuticals LLC | February 20, 2026 | |
| To Be Discontinued | Docetaxel Injection | Docetaxel, Injection, 10 mg/1 mL (NDC 50742-463-16) | Ingenus Pharmaceuticals LLC | February 20, 2026 | |
| To Be Discontinued | Carboplatin Injection | Carboplatin, Injection, 600 mg/60 mL (NDC 50742-448-60) | Ingenus Pharmaceuticals LLC | February 20, 2026 | |
| To Be Discontinued | Decitabine Injection | Decitabine, Injection, 50 mg (NDC 50742-430-01) | Ingenus Pharmaceuticals LLC | February 20, 2026 | |
| To Be Discontinued | Allopurinol Tablet | Allopurinol, Tablet, 300 mg (NDC 0591-5544-05) | Teva Pharmaceuticals USA, Inc. | February 19, 2026 | |
| To Be Discontinued | Allopurinol Tablet | Allopurinol, Tablet, 100 mg (NDC 0591-5543-10) | Teva Pharmaceuticals USA, Inc. | February 19, 2026 | |
| To Be Discontinued | Allopurinol Tablet | Allopurinol, Tablet, 300 mg (NDC 0591-5544-01) | Teva Pharmaceuticals USA, Inc. | February 19, 2026 | |
| To Be Discontinued | Allopurinol Tablet | Allopurinol, Tablet, 100 mg (NDC 0591-5543-01) | Teva Pharmaceuticals USA, Inc. | February 19, 2026 | |
| To Be Discontinued | Chlorothiazide Oral Suspension | Diuril, Oral Suspension, 250 mg/5mL (NDC 65649-311-12) | Salix Pharmaceuticals, a division of Bausch Health US, LLC | February 10, 2026 | |
| To Be Discontinued | Cefepime Hydrochloride Injection | Cefepime Hydrochloride, Injection, 1 g (NDC 63323-326-20) | Fresenius Kabi USA, LLC | February 10, 2026 | |
| To Be Discontinued | Gemfibrozil Tablet | Lopid, Tablet, 600 mg (NDC 0071-0737-20) | Pfizer Inc. | February 10, 2026 | |
| To Be Discontinued | Cefepime Hydrochloride Injection | Cefepime Hydrochloride, Injection, 2 g (NDC 63323-340-20) | Fresenius Kabi USA, LLC | February 10, 2026 | |
| To Be Discontinued | Pindolol Tablet | Pindolol, Tablet, 5 mg (NDC 57664-655-88) | Sun Pharmaceutical Industries, Inc. | January 30, 2026 | |
| To Be Discontinued | Pindolol Tablet | Pindolol, Tablet, 10 mg (NDC 57664-656-88) | Sun Pharmaceutical Industries, Inc. | January 30, 2026 | |
| To Be Discontinued | Podofilox Topical Gel | Condylox , Topical Gel, 0.5% (NDC 0023-6118-03) | AbbVie Inc. | January 28, 2026 | |
| To Be Discontinued | Benztropine Mesylate Injection | Benztropine Mesylate, Injection, 1 mg/1 mL (NDC 63323-970-02) | Fresenius Kabi USA, LLC | January 27, 2026 | |
| To Be Discontinued | Fluvastatin Sodium Tablet, Extended Release | Lescol XL, Tablet, Extended Release, 80 mg (NDC 66758-211-31) | Sandoz Inc. | January 27, 2026 | |
| To Be Discontinued | Fluvastatin Sodium Tablet, Extended Release | Fluvastatin Sodium, Tablet, Extended Release, 80 mg (NDC 0781-8017-31) | Sandoz Inc. | January 27, 2026 | |
| To Be Discontinued | Fluvastatin Sodium Tablet, Extended Release | Fluvastatin Sodium, Tablet, Extended Release, 80 mg (NDC 0781-8017-01) | Sandoz Inc. | January 27, 2026 | |
| To Be Discontinued | Piperacillin and Tazobactam Injection | Piperacillin and Tazobactam, Injection, 2.25 g vial (NDC 65219-434-20) | Fresenius Kabi USA, LLC | January 20, 2026 | |
| To Be Discontinued | Riboflavin 5-phosphate Ophthalmic Solution | Photrexa Cross-linking Kit, Ophthalmic Solution, Kit (NDC 25357-025-03) | Glaukos Corporation | January 20, 2026 | |
| To Be Discontinued | Maraviroc Solution | Selzentry, Solution, 20 mg/mL Oral Solution Kit | 230 mL Oral Solution per Bottle | 1… | ViiV Healthcare Company | January 20, 2026 | |
| To Be Discontinued | Azithromycin Injection | Zithromax IV, Injection, 500 mg/5 mL (NDC 0069-3150-83) | Pfizer Inc. | January 20, 2026 | |
| To Be Discontinued | Adalimumab-adaz Injection | Hyrimoz, Injection, Kit (NDC 61314-517-36) | Sandoz Inc. | January 13, 2026 | |
| To Be Discontinued | Adalimumab-adaz Injection | Hyrimoz, Injection, Kit (NDC 61314-531-64) | Sandoz Inc. | January 13, 2026 | |
| To Be Discontinued | Adalimumab-adaz Injection | Hyrimoz, Injection, 80 mg/.8 mL (NDC 61314-454-36) | Sandoz Inc. | January 13, 2026 | |
| To Be Discontinued | Adalimumab-adaz Injection | Hyrimoz, Injection, 80 mg/.8 mL (NDC 61314-454-68) | Sandoz Inc. | January 13, 2026 | |
| To Be Discontinued | Adalimumab-adaz Injection | Hyrimoz, Injection, 40 mg/.4 mL (NDC 61314-473-64) | Sandoz Inc. | January 13, 2026 | |
| To Be Discontinued | Neostigmine Methylsulfate Injection | Neostigmine Methylsulfate, Injection, .5 mg/1 mL (NDC 63323-413-10) | Fresenius Kabi USA, LLC | January 12, 2026 | |
| To Be Discontinued | Doxycycline Hyclate Tablet | Doxycycline Hyclate, Tablet, 100 mg (NDC 0378-0167-02) | Mylan Pharmaceuticals Inc., a Viatris Company | January 12, 2026 | |
| To Be Discontinued | Doxycycline Hyclate Tablet | Doxycycline Hyclate, Tablet, 100 mg (NDC 0378-0167-13) | Mylan Pharmaceuticals Inc., a Viatris Company | January 12, 2026 | |
| To Be Discontinued | Doxylamine Succinate and Pyridoxine Hydrochloride Tablet, Delayed Release | Doxylamine Succinate and Pyridoxine Hydrochloride, Tablet, Delayed Release, 10 mg; 10 mg… | Mylan Pharmaceuticals Inc., a Viatris Company | January 12, 2026 | |
| To Be Discontinued | Caspofungin Acetate Injection | Caspofungin Acetate, Injection, 7 mg/1 mL (NDC 63323-358-10) | Fresenius Kabi USA, LLC | January 12, 2026 | |
| To Be Discontinued | Haloperidol Decanoate Injection | Haloperidol Decanoate, Injection, 50 mg/1 mL (NDC 63323-469-05) | Fresenius Kabi USA, LLC | January 9, 2026 | |
| To Be Discontinued | Haloperidol Decanoate Injection | Haloperidol Decanoate, Injection, 50 mg/1 mL (NDC 63323-469-01) | Fresenius Kabi USA, LLC | January 9, 2026 | |
| To Be Discontinued | Imipenem and Cilastatin Injection | Primaxin, Injection, 500mg (NDC 0006-3516-59) | Merck Sharp & Dohme Corp. | January 8, 2026 | |
| To Be Discontinued | Everolimus Tablet | Everolimus, Tablet, 7.5 mg (NDC 49884-127-91) | Endo Pharmaceuticals, Inc. | January 6, 2026 | |
| To Be Discontinued | Everolimus Tablet | Everolimus, Tablet, 10 mg (NDC 49884-128-91) | Endo Pharmaceuticals, Inc. | January 6, 2026 | |
| To Be Discontinued | Everolimus Tablet | Everolimus, Tablet, 2.5 mg (NDC 49884-119-91) | Endo Pharmaceuticals, Inc. | January 6, 2026 | |
| To Be Discontinued | Everolimus Tablet | Everolimus, Tablet, 5 mg (NDC 49884-125-91) | Endo Pharmaceuticals, Inc. | January 6, 2026 | |
| To Be Discontinued | Diltiazem Hydrochloride Injection | Diltiazem Hydrochloride, Injection, 100 mg Single Dose ADD-Vantage® Glass Vial (NDC… | Hospira, Inc., a Pfizer Company | January 5, 2026 | |
| To Be Discontinued | Hydroxychloroquine Sulfate Tablet | Hydroxychloroquine Sulfate, Tablet, 200 mg (NDC 0093-2401-01) | Teva Pharmaceuticals USA, Inc. | January 5, 2026 | |
| To Be Discontinued | Sodium Oxybate Solution | Sodium Oxybate, Solution, .5 g/1 mL (NDC 69238-2391-1) | Amneal Pharmaceuticals | December 29, 2025 | |
| To Be Discontinued | Morphine Sulfate Tablet | Morphine Sulfate, Tablet, 15 mg (NDC 0832-0273-11) | Upsher-Smith Laboratories, LLC | December 22, 2025 | |
| To Be Discontinued | Mirikizumab-mrkz Injection | Omvoh, Injection, 100 mg/1 mL (NDC 0002-8870-27) | Eli Lilly and Co. | December 22, 2025 | |
| To Be Discontinued | Morphine Sulfate Tablet | Morphine Sulfate, Tablet, 30 mg (NDC 0832-0274-11) | Upsher-Smith Laboratories, LLC | December 22, 2025 | |
| To Be Discontinued | Mirikizumab-mrkz Injection | Omvoh, Injection, 100 mg/1 mL (NDC 0002-8011-27) | Eli Lilly and Co. | December 22, 2025 | |
| To Be Discontinued | Carbamazepine Capsule, Extended Release | Carbatrol, Capsule, Extended Release, 100 mg (NDC 54092-171-12) | Takeda Pharmaceuticals USA Inc. | December 19, 2025 | |
| To Be Discontinued | Carbamazepine Capsule, Extended Release | Carbatrol, Capsule, Extended Release, 300 mg (NDC 54092-173-12) | Takeda Pharmaceuticals USA Inc. | December 19, 2025 | |
| To Be Discontinued | Carbamazepine Capsule, Extended Release | Carbatrol, Capsule, Extended Release, 200 mg (NDC 54092-172-12) | Takeda Pharmaceuticals USA Inc. | December 19, 2025 | |
| To Be Discontinued | Doxercalciferol Injection | Hectorol, Injection, 4 mcg/2 mL injection 50 multiple-dose vials (NDC 58468-0127-1) | Sanofi-Aventis U.S. LLC | December 10, 2025 | |
| To Be Discontinued | Spironolactone Tablet | Aldactone, Tablet, 100 mg (NDC 0025-1031-31) | Pfizer Inc. | December 10, 2025 | |
| To Be Discontinued | Doxercalciferol Injection | Hectorol, Injection, 4 mcg/2 mL injection 50 single-dose vials (NDC 58468-0123-1) | Sanofi-Aventis U.S. LLC | December 10, 2025 | |
| To Be Discontinued | Doxercalciferol Injection | Hectorol, Injection, 2 mcg/mL injection 50 single-dose vials (NDC 58468-0126-1) | Sanofi-Aventis U.S. LLC | December 10, 2025 | |
| To Be Discontinued | Spironolactone Tablet | Aldactone, Tablet, 25 mg (NDC 0025-1001-31) | Pfizer Inc. | December 10, 2025 | |
| To Be Discontinued | Ampicillin Sodium Injection | Ampicillin Sodium, Injection, 10 g (NDC 0781-9409-95) | Sandoz Inc. | December 8, 2025 | |
| To Be Discontinued | Ampicillin Sodium Injection | Ampicillin Sodium, Injection, 1 g (NDC 0781-9412-92) | Sandoz Inc. | December 8, 2025 | |
| To Be Discontinued | Ampicillin Sodium Injection | Ampicillin Sodium, Injection, 2 g (NDC 0781-9408-95) | Sandoz Inc. | December 8, 2025 | |
| To Be Discontinued | Ampicillin Sodium Injection | Ampicillin Sodium, Injection, 2 g (NDC 0781-9413-92) | Sandoz Inc. | December 8, 2025 | |
| To Be Discontinued | Ampicillin Sodium Injection | Ampicillin Sodium, Injection, 1 g (NDC 0781-9404-95) | Sandoz Inc. | December 8, 2025 | |
| To Be Discontinued | Calcitriol Capsule | Calcitriol, Capsule, .25 ug (NDC 0093-7352-01) | Teva Pharmaceuticals USA, Inc. | December 4, 2025 | |
| To Be Discontinued | Calcitriol Capsule | Calcitriol, Capsule, .5 ug (NDC 0093-7353-01) | Teva Pharmaceuticals USA, Inc. | December 4, 2025 | |
| To Be Discontinued | Sodium Chloride 0.9% Injection | Sodium Chloride 0.9%, Injection, 250 mL ADD-Vantage® Flexible Container (NDC 0409-7101-02) | Hospira, Inc., a Pfizer Company | December 3, 2025 | |
| To Be Discontinued | Sodium Chloride 0.9% Injection | Sodium Chloride 0.9%, Injection, 100 mL ADD-Vantage® Flexible Container (NDC 0409-7101-67) | Hospira, Inc., a Pfizer Company | December 3, 2025 | |
| To Be Discontinued | Sodium Chloride 0.9% Injection | Sodium Chloride 0.9%, Injection, 50 mL ADD-Vantage® Flexible Container (NDC 0409-7101-66) | Hospira, Inc., a Pfizer Company | December 3, 2025 | |
| To Be Discontinued | Posaconazole Injection | Noxafil, Injection, 18 mg/1 mL (NDC 0085-4331-01) | Merck Sharp & Dohme Corp. | December 2, 2025 | |
| To Be Discontinued | Phenoxybenzamine Hydrochloride Capsule | Dibenzyline, Capsule, 10 mg (NDC 59212-001-01) | Advanz Pharma (US) Corp. | December 1, 2025 | |
| To Be Discontinued | Phenoxybenzamine Hydrochloride Capsule | Dibenzyline, Capsule, 10 mg (NDC 59212-001-02) | Advanz Pharma (US) Corp. | December 1, 2025 | |
| To Be Discontinued | Nilutamide Tablet | Nilandron, Tablet, 150 mg (NDC 59212-111-14) | Advanz Pharma (US) Corp. | December 1, 2025 | |
| To Be Discontinued | Nilutamide Tablet | Nilandron, Tablet, 150 mg (NDC 66993-212-38) | Advanz Pharma (US) Corp. | December 1, 2025 | |
| To Be Discontinued | Phenoxybenzamine Hydrochloride Capsule | Dibenzyline, Capsule, 10 mg (NDC 66993-066-02) | Advanz Pharma (US) Corp. | December 1, 2025 | |
| To Be Discontinued | Verapamil Hydrochloride Injection | Verapamil Hydrochloride, Injection, 2.5 mg/1 mL (NDC 0409-9633-05) | Pfizer Inc. | November 21, 2025 | |
| To Be Discontinued | Potassium Chloride Tablet, Extended Release | Potassium Chloride, Tablet, Extended Release, 20 meq (NDC 62037-720-01) | Teva Pharmaceuticals USA, Inc. | November 21, 2025 | |
| To Be Discontinued | Potassium Chloride Tablet, Extended Release | Potassium Chloride, Tablet, Extended Release, 20 meq (NDC 62037-720-05) | Teva Pharmaceuticals USA, Inc. | November 21, 2025 | |
| To Be Discontinued | Potassium Chloride Tablet, Extended Release | Potassium Chloride, Tablet, Extended Release, 10 meq (NDC 62037-710-01) | Teva Pharmaceuticals USA, Inc. | November 21, 2025 | |
| To Be Discontinued | Potassium Chloride Tablet, Extended Release | Potassium Chloride, Tablet, Extended Release, 20 meq (NDC 62037-720-10) | Teva Pharmaceuticals USA, Inc. | November 21, 2025 | |
| To Be Discontinued | Anagrelide Hydrochloride Capsule | Anagrelide Hydrochloride, Capsule, 1 mg (NDC 0172-5240-60) | Teva Pharmaceuticals USA, Inc. | November 19, 2025 | |
| To Be Discontinued | Valsartan Tablet | Valsartan, Tablet, 40 mg (NDC 0378-5807-93) | Mylan Pharmaceuticals Inc., a Viatris Company | November 19, 2025 | |
| To Be Discontinued | Valsartan Tablet | Valsartan, Tablet, 160 mg (NDC 0378-5814-77) | Mylan Pharmaceuticals Inc., a Viatris Company | November 19, 2025 | |
| To Be Discontinued | Anagrelide Hydrochloride Capsule | Anagrelide Hydrochloride, Capsule, 0.5 mg (NDC 0172-5241-60) | Teva Pharmaceuticals USA, Inc. | November 19, 2025 | |
| To Be Discontinued | Valsartan Tablet | Valsartan, Tablet, 320 mg (NDC 0378-5815-77) | Mylan Pharmaceuticals Inc., a Viatris Company | November 19, 2025 | |
| To Be Discontinued | Hydrochlorothiazide Capsule | Microzide, Capsule, 12.5 mg (NDC 0591-0347-01) | Teva Pharmaceuticals USA, Inc. | November 19, 2025 | |
| To Be Discontinued | Valsartan Tablet | Valsartan, Tablet, 80 mg (NDC 0378-5813-77) | Mylan Pharmaceuticals Inc., a Viatris Company | November 19, 2025 | |
| To Be Discontinued | Hydrochlorothiazide Capsule | Microzide, Capsule, 12.5 mg (NDC 0591-0347-05) | Teva Pharmaceuticals USA, Inc. | November 19, 2025 | |
| To Be Discontinued | Montelukast Sodium Tablet, Chewable | Singulair, Tablet, Chewable, 4 mg (NDC 78206-170-01) | Organon | November 17, 2025 |